// App-Quantinova.ai

268 : Tislelizumab versus chemotherapy as second-line treatment for advanced or metastatic esophageal squamous cell carcinoma (ESCC, RATIONALE 302): Impact on health-related quality of life (HRQoL).

Researchers

Presenter

  • Eric Van Cutsem

Principal Investigators

  • Ken Kato

  • Jaffer A. Ajani

  • Lin Shen

  • Tianyu Xia

  • Ningning Ding

  • Lin Zhan

  • Gisoo Barnes

  • Sung-Bae Kim

Medical Centers

  • University of Leuven (KUL) and University Hospitals Gasthuisberg, Leuven, Belgium

  • The University of Texas MD Anderson Cancer Canter, Houston, TX

  • Department of Thoracic Medical Oncology, Peking University Cancer Hospital & Institute, Beijing, China

  • BeiGene Ltd., Cambridge, MA

  • BeiGene Ltd, Zhongguancun Life Science Park, Beijing, China

  • BeiGene, San Mateo, CA

  • BeiGene, Ltd., Emeryville, CA

  • Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea

Locations

  • Belgium

  • Japan

  • United States

  • China

  • Republic of South Korea

Companies

  • BeiGene USA, Inc.

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Esophageal squamous carcinoma cell

Biomarkers

  • N/A

Drug/Treatment

  • Tislelizumab

  • Irinotecan

  • Paclitaxel

  • Docetaxel

Outcome

  • N/A

Study Design

  • Randomized

Phase

  • III

Study Id's

  • NCT03430843

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved